Case-control study of reasons for presentation of nonmelanocytic skin cancers at an advanced stage. [ 2000 - 2002 ]

Research Grant

Researchers: Prof Bruce Armstrong (Principal investigator)

Brief description There are about four times as many skin cancers treated in Australia each year as all other cancers combined and the vast majority of these are the nonmelanocytic skin cancers (NMSC). While most of these cancers are easily treatable, a proportion of these cancers are not given potentially effective treatment until the cancer has reached an advanced stage. Preliminary results from our pilot studies indicate that at least 50% of patients with NMSC who are treated with radiotherapy and 92% of NMSC patients treated with a graft or flap surgical procedure by the dermatologists in Newcastle are so treated because of the extent of disease at the primary site. These advanced stage cancers make an important contribution to the 70,000 admissions to hospital for the treatment of NMSC each year in Australia. The total direct health services cost of treatment of these skin cancers was estimated to be $232,000,000 in 1993-94, which was more than for any other type of cancer. Some 379 people died from nonmelanocytic skin cancer in Australia in 1993 and these were all potentially preventable deaths. The study aims are therefore to: 1. Measure the contributions of delay in seeking treatment and inadequate inital treatment to the need for treatment of skin cancer at an advanced stage. 2. Ascertain the factors that are associated with delay in seeking treatment for skin cancer until it has reached an advanced stage. This study will be the first substantial and population-based study of advanced skin cancer and the factors that underlie it. It will give the first empirical guidance to the design of initiatives to prevent the development of advanced skin cancer, a major area of cost to Australian health services. The study will increase understanding of why some skin cancers are not treated definitively until they reach an advanced stage and guide the development of interventions to reduce the frequency of patients who present with advanced stage skin cancer.

Funding Amount $AUD 250,614.09

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant